Physician profile
Indley Johnson
NPI 1689037665
$3,471.25
in general payments reported to CMS, 2019-2025
20 companies · $393 in 2025
The $393 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $275 · 2022: $444 · 2023: $1,023 · 2024: $1,212 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.86 |
| Education | $113.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $949.09 | 2022-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $899.29 | 2019-2024 | Fasenra, Airsupra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $277.90 | 2022-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $170.35 | 2021-2024 | Tyvaso |
| Ethicon INC. | $147.10 | 2023 | Monarch Platform |
| Edwards Lifesciences Corporation | $138.58 | 2023 | Sapien 3 Ultra Resilia |
| Abiomed | $133.33 | 2024 | Impella |
| Verona Pharma, INC. | $125.00 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $106.68 | 2023-2024 | |
| Amgen INC. | $104.63 | 2023-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $79.94 | 2024 | Dupixent |
| Resmed Corp | $75.79 | 2023 | |
| Inspire Medical Systems, INC. | $71.83 | 2024 | Inspire |
| Pulmonx Corporation | $63.81 | 2024-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Avadel Cns Pharmaceuticals, LLC | $27.47 | 2025 | Lumryz |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $26.87 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.79 | 2023 | Glassia |
| Janssen Pharmaceuticals, INC | $17.94 | 2021 | |
| Insmed, INC. | $17.19 | 2024 | Arikayce |
| Icu Medical INC | $16.67 | 2024 | Tracheostomy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indley Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.